Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer
NCT00020722
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation plus biological therapy may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This phase II trial is studying how well chemotherapy followed by peripheral stem cell transplantation plus biological therapy works in treating women with stage IV breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
02/15/2016
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Breast Cancer
Register for Updates
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
NCT00533585
Completed
The goal of this study is to find the highest tolerable dose of BAY 43-9006 (sorafenib) and bevacizumab that can be given with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). The safety and effectiveness of this drug combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2016
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates
Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery
NCT00769470
Completed
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Lapatinib may stop the growth of tumor cells by blocking some of the enzyme... Read More
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
01/20/2016
Locations: Central Hematology Oncology Medical Group, Incorporated - Alhambra, Alhambra, California +14 locations
Conditions: Breast Cancer
Register for Updates
Combination Paclitaxel, Carboplatin and Temozolomide
NCT00249964
Completed
The purpose of this study is to determine the maximum tolerable dose of temozolomide in combination with fixed dose of paclitaxel and carboplatin and to determine the overall tumor response rate with this combination and to determine the duration of response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2016
Locations: University of New Mexico Cancer Center, Albuquerque, New Mexico
Conditions: Lung Diseases, Cancer
Register for Updates
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors
NCT00008125
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase I trial to study the effectiveness of gemcitabine combined with docetaxel and carboplatin with or without filgrastim in treating patients who have advan... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
01/14/2016
Locations: University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
NCT01916109
Terminated
The purpose of this study is to find out if using the combination of standard chemotherapy (gemcitabine and carboplatin) plus this new drug (panitumumab) can help to shrink the tumor before the patient undergoes surgery for bladder cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2016
Locations: Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey +4 locations
Conditions: Bladder Cancer
Register for Updates
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma
NCT01200342
Terminated
The goal of this clinical research is to learn if the combination of Genasense (oblimersen), carboplatin, and paclitaxel (GCP) can help to control metastatic uveal melanoma. The safety of this combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2016
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Melanoma
Register for Updates
Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma
NCT00255723
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Radiation therapy uses high-energy x-rays to kill cancer cells. Giving combination chemotherapy and radiation therapy with an autologous stem cell transplant, using peripheral stem cells or bone marrow from the patient, may allow more chemotherapy to be given... Read More
Gender:
ALL
Ages:
Between 18 years and 72 years
Trial Updated:
12/22/2015
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Lymphoma
Register for Updates
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
NCT00006453
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if carboplatin is more effective with or without gemcitabine for ovarian epithelial cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of carboplatin with or without gemcitabine in treating patients who have advanced ovarian epithelial cancer that has not responded to previous che... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
12/22/2015
Locations: St. Mary's/Duluth Clinic Health System, Duluth, Minnesota +73 locations
Conditions: Ovarian Cancer
Register for Updates
BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
NCT01624493
Withdrawn
This phase I/II trial will determine the recommended dose and activity of BNC105P for patients with partially platinum sensitive ovarian cancer in first or second relapse.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/21/2015
Locations: University of Chicago, Chicago, Illinois +5 locations
Conditions: Ovarian Cancer
Register for Updates
Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
NCT00003631
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus radiation th... Read More
Gender:
ALL
Ages:
120 years and below
Trial Updated:
12/17/2015
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Lymphoma
Register for Updates
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
NCT00588666
Completed
Gemcitabine and carboplatin are two standard chemotherapy drugs used to treat tumors of the urothelial tract. These drugs do not shrink tumors in all patients and when they do, it is generally for a limited amount of time. This has led scientists to look for different ways to treat cancer. New drugs have been developed to treat cancer that work differently than standard chemotherapy drugs. One new class of drugs are called 'angiogenesis-inhibitors'. These drugs attempt to decrease the blood sup... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2015
Locations: Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey +5 locations
Conditions: Myeloproliferative Disorder, Urothelial Carcinoma, Cancer
Register for Updates